Table 3 Potency conversion of DOAC

Molecular weight (Da)

436

628

460

548

(a) Molecular weight ratio to rivaroxaban

1

1.44

1.06

1.26

Bioavailability (%)

90*^a

6.5

66

47.5*^c

(b) Bioavailability ratio to rivaroxaban

1

13.85

1.36

1.89

Protein binding (%)

93.5*^b

35

87

49.5*^d

(c) Protein-binding ratio to rivaroxaban

1

0.37

0.93

0.53

Inhibitory constant; Ki (nM)

0.4

4.5

0.08

0.56

(d) Ki ratio to rivaroxaban

1

11.25

0.20

1.40

(A) Total ratio to rivaroxaban = (a)X(b)X(c)X(d)

1

83.99

0.27

1.77

(B) SPAF customary daily dose (mg)

20

300

10

60

Potency conversion; matching dose for customary dose of rivaroxaban (B)/(A)

20

3.57

37.35

33.99

(C) SPAF reduced daily dose (mg)

15

220

5

30

Potency conversion; matching dose for reduced dose of rivaroxaban (C)/(A)

15

2.62

18.68

17.00